Literature DB >> 24809810

PET imaging in multiple sclerosis.

Daniele de Paula Faria1, Sjef Copray, Carlos Buchpiguel, Rudi Dierckx, Erik de Vries.   

Abstract

Positron emission tomography (PET) is a non-invasive technique for quantitative imaging of biochemical and physiological processes in animals and humans. PET uses probes labeled with a radioactive isotope, called PET tracers, which can bind to or be converted by a specific biological target and thus can be applied to detect and monitor different aspects of diseases. The number of applications of PET imaging in multiple sclerosis is still limited. Clinical studies using PET are basically focused on monitoring changes in glucose metabolism and the presence of activated microglia/macrophages in sclerotic lesions. In preclinical studies, PET imaging of targets for other processes, like demyelination and remyelination, has been investigated and may soon be translated to clinical applications. Moreover, more PET tracers that could be relevant for MS are available now, but have not been studied in this context yet. In this review, we summarize the PET imaging studies performed in multiple sclerosis up to now. In addition, we will identify potential applications of PET imaging of processes or targets that are of interest to MS research, but have yet remained largely unexplored.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24809810     DOI: 10.1007/s11481-014-9544-2

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  118 in total

1.  Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis.

Authors:  J B Johnston; C Silva; G Gonzalez; J Holden; K G Warren; L M Metz; C Power
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

Review 2.  Principles of nuclear medicine imaging: planar, SPECT, PET, multi-modality, and autoradiography systems.

Authors:  Pat Zanzonico
Journal:  Radiat Res       Date:  2012-02-27       Impact factor: 2.841

Review 3.  Pathology of demyelinating diseases.

Authors:  Bogdan F Gh Popescu; Claudia F Lucchinetti
Journal:  Annu Rev Pathol       Date:  2012       Impact factor: 23.472

4.  Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [¹⁸F]DPA-714.

Authors:  Galith Abourbeh; Benoit Thézé; Renaud Maroy; Albertine Dubois; Vincent Brulon; Yoann Fontyn; Frédéric Dollé; Bertrand Tavitian; Raphaël Boisgard
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

Review 5.  Brain imaging of multiple sclerosis: the next 10 years.

Authors:  Paul M Matthews
Journal:  Neuroimaging Clin N Am       Date:  2009-02       Impact factor: 2.264

6.  Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment.

Authors:  Jere R Virta; Sari Laatu; Riitta Parkkola; Vesa Oikonen; Juha O Rinne; Juhani Ruutiainen
Journal:  Mult Scler       Date:  2011-03-03       Impact factor: 6.312

7.  Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.

Authors:  Md Jashim Uddin; Brenda C Crews; Kebreab Ghebreselasie; Imran Huda; Philip J Kingsley; Mohammad Sib Ansari; Mohammed N Tantawy; Jeffery Reese; Lawrence J Marnett
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-07

Review 8.  The pathology of MS: new insights and potential clinical applications.

Authors:  Sean J Pittock; Claudia F Lucchinetti
Journal:  Neurologist       Date:  2007-03       Impact factor: 1.398

9.  Regional regulation of glutamate signaling during cuprizone-induced demyelination in the brain.

Authors:  Abolfazl Azami Tameh; Tim Clarner; Cordian Beyer; Mohammad Ali Atlasi; Gholamreza Hassanzadeh; Homayoun Naderian
Journal:  Ann Anat       Date:  2013-04-28       Impact factor: 2.698

10.  The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis.

Authors:  Noel G Carlson; Kenneth E Hill; Ikuo Tsunoda; Robert S Fujinami; John W Rose
Journal:  J Neuroimmunol       Date:  2006-03-03       Impact factor: 3.478

View more
  12 in total

Review 1.  11C-methionine PET/CT findings in benign brain disease.

Authors:  Reiko Nakajima; Ken Kimura; Koichiro Abe; Shuji Sakai
Journal:  Jpn J Radiol       Date:  2017-04-18       Impact factor: 2.374

Review 2.  Cognitive impairment and World Trade Centre-related exposures.

Authors:  Sean A P Clouston; Charles B Hall; Minos Kritikos; David A Bennett; Steven DeKosky; Jerri Edwards; Caleb Finch; William C Kreisl; Michelle Mielke; Elaine R Peskind; Murray Raskind; Marcus Richards; Richard P Sloan; Avron Spiro; Neil Vasdev; Robert Brackbill; Mark Farfel; Megan Horton; Sandra Lowe; Roberto G Lucchini; David Prezant; Joan Reibman; Rebecca Rosen; Kacie Seil; Rachel Zeig-Owens; Yael Deri; Erica D Diminich; Bernadette A Fausto; Sam Gandy; Mary Sano; Evelyn J Bromet; Benjamin J Luft
Journal:  Nat Rev Neurol       Date:  2021-11-18       Impact factor: 42.937

Review 3.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 4.  Imaging outcome measures for progressive multiple sclerosis trials.

Authors:  Marcello Moccia; Nicola de Stefano; Frederik Barkhof
Journal:  Mult Scler       Date:  2017-10       Impact factor: 6.312

Review 5.  Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases.

Authors:  Anne-Claire Dupont; Bérenger Largeau; Maria Joao Santiago Ribeiro; Denis Guilloteau; Claire Tronel; Nicolas Arlicot
Journal:  Int J Mol Sci       Date:  2017-04-07       Impact factor: 5.923

Review 6.  Neonatal brain resting-state functional connectivity imaging modalities.

Authors:  Ali-Reza Mohammadi-Nejad; Mahdi Mahmoudzadeh; Mahlegha S Hassanpour; Fabrice Wallois; Otto Muzik; Christos Papadelis; Anne Hansen; Hamid Soltanian-Zadeh; Juri Gelovani; Mohammadreza Nasiriavanaki
Journal:  Photoacoustics       Date:  2018-02-02

7.  18F-VC701-PET and MRI in the in vivo neuroinflammation assessment of a mouse model of multiple sclerosis.

Authors:  Sara Belloli; Lucia Zanotti; Valentina Murtaj; Cristina Mazzon; Giuseppe Di Grigoli; Cristina Monterisi; Valeria Masiello; Leonardo Iaccarino; Andrea Cappelli; Pietro Luigi Poliani; Letterio Salvatore Politi; Rosa Maria Moresco
Journal:  J Neuroinflammation       Date:  2018-02-05       Impact factor: 8.322

8.  Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.

Authors:  Elisa Schmidt; Christian Schinke; Michael Rullmann; Julia Luthardt; Georg-Alexander Becker; Sarah Haars; Muriel Stoppe; Donald Lobsien; Karl-Titus Hoffmann; Osama Sabri; Swen Hesse; Florian Then Bergh
Journal:  Sci Rep       Date:  2020-09-04       Impact factor: 4.379

9.  Detecting Demyelination by PET: The Lesion as Imaging Target.

Authors:  Pedro Brugarolas; Daniel S Reich; Brian Popko
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

Review 10.  Precision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive Astrocytes.

Authors:  Pekka Poutiainen; Merja Jaronen; Francisco J Quintana; Anna-Liisa Brownell
Journal:  Front Mol Neurosci       Date:  2016-09-15       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.